论文部分内容阅读
目的:深入了解2017年版《国家基本医疗保险、工伤保险和生育保险药品目录》(以下简称2017年版《药品目录》)西药品种。方法:比较2017年版《药品目录》与2009年版《药品目录》西药品种的差异。利用《医院处方分析合作项目》的处方数据,对2017年版《药品目录》中重点关注的西药品种进行处方金额分析(仅到药品名称层级,不区分剂型)。结果和结论:2017年版《药品目录》明显扩大了基本医疗保险用药保障范围、提高了用药保障水平,有利于减轻广大参保人员目录外药品费用负担,有利于我国医药产业创新发展。
Purpose: To learn more about the 2017 edition of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List” (hereinafter referred to as 2017 version of the “Drug List”) western medicine varieties. Methods: To compare the differences between the 2017 version of “Drug List” and the 2009 edition of “Drug List” for western medicine. Using the prescribing data of the “Hospital Prescription Analysis Cooperative Project”, the prescription amount analysis (only at the level of the drug name, without distinction of dosage forms) was conducted on the varieties of western medicines that are of major concern in the 2017 version of the “Drug List.” RESULTS AND CONCLUSION: The 2017 version of “Drug List” significantly expanded the scope of Medicare coverage, improved the level of medication security, reduced the burden of extra-territorial drug charges on the vast majority of participants, and contributed to the innovation and development of China’s pharmaceutical industry.